Bicycle Drug Conjugates: Precision Peptide Therapy Targeting EphA2 in Cancer | Research

The takeaway

Bicycle drug conjugates offer a new peptide-based approach to precisely target EphA2-expressing solid tumors, overcoming limitations of previous EphA2 therapies.

Next-gen after 4 failures
BDCs aim to succeed where MEDI-547, DS-8895a, MM-310, and dasatinib could not

What the researchers found

Bicycle drug conjugates represent a novel peptide-based approach to targeting EphA2 in solid tumors, potentially overcoming the efficacy and safety limitations of previous EphA2-targeting agents.

Why it matters

Pancreatic and head-and-neck cancers have very poor survival rates. New precision therapies targeting EphA2 could provide treatment options where few currently exist.

How the study worked

Review of EphA2 as a cancer target, previous therapeutic failures, and the emerging bicycle drug conjugate platform as a next-generation approach.

What this study cannot tell us

Review article — BDCs targeting EphA2 are still in development. Clinical efficacy and safety data are limited or pending.

How to read the evidence

Review of a drug development platform — summarizes preclinical rationale and early clinical data for a novel approach.

When this study was published

Published in 2026; covers the latest BDC development pipeline.

The bigger picture

Bicycle drug conjugates represent a broader shift in oncology toward engineered peptide therapeutics that combine the targeting precision of antibodies with the tissue penetration of small molecules.

Questions still open

Will BDCs targeting EphA2 succeed where antibody-drug conjugates failed?
Can the bicycle peptide platform be applied to other difficult tumor targets?

Common questions

What are bicycle drug conjugates?

BDCs are small engineered peptides shaped like a bicycle wheel (two connected rings) that can precisely bind tumor targets and deliver attached cancer-killing drugs directly to tumor cells, with better tissue penetration than larger antibodies.

What is EphA2?

EphA2 is a receptor protein found at high levels on many aggressive solid tumors. Its overexpression is linked to poor prognosis, making it an attractive target for precision cancer therapies.

Read the original research

Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates.

Journal of translational medicine, 24(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Bennett, Gavin; Riedl, Jitka; Mudd, Gemma. (2026). Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates.. Journal of translational medicine, 24(1). https://doi.org/10.1186/s12967-026-07870-3